Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 47 resultados

PAVax: A training network for the design of new synthetic carbohydrate based vaccines to combat antibiotic... GlaxoSmithKline Vaccines Srl participó en un H2020: H2020-MSCA-ITN-2019 PAVax is a network that will train 4 early-stage researchers (ESRs) on the conception of new synthetic vaccines to combat the antibiotic res...
2019-11-29 - 2024-08-31 | Financiado

PHA-ST-TRAIN-VAC: Leveraging Pharmaceutical Sciences and Structural Biology Training to develop 21st Century Vaccines GlaxoSmithKline Vaccines Srl participó en un H2020: H2020-MSCA-ITN-2015 Immunisation is one of the most cost-effective and proven tools to control and eliminate infectious diseases, saving millions of lives each...
2016-06-30 - 2020-05-31 | Financiado

VADEMA: Doctoral Industrial School for Vaccine Design through Structural Mass Spectrometry GlaxoSmithKline Vaccines Srl tramitó un H2020: H2020-MSCA-ITN-2015 Vaccines discovered from empirical approaches and consisting in killed, live-attenuated microorganisms or purified components have led to th...
2016-03-17 - 2020-10-31 | Financiado

DISSection: Doctoral Industrial School on Human Skin models for Staphylococcal infections GlaxoSmithKline Vaccines Srl tramitó un H2020: H2020-MSCA-ITN-2015 Staphylococcus aureus (S. aureus) is a major human pathogen and cutaneous infections are among the leading cause of emergency department vis...
2016-03-17 - 2020-10-31 | Financiado

GLYCOVAX: A training network for the rational design of the next generation of well defined glycoconjugate vac... GlaxoSmithKline Vaccines Srl tramitó un H2020: H2020-MSCA-ITN-2015 GLYCOVAX is a network for the education of promising young scientists who will learn how to rationally design a next generation of well-defi...
2015-08-11 - 2019-10-31 | Financiado

SVNanoVax: Structural Vaccinology in the design of bionanoparticles with multi copy antigen display for vaccine... GlaxoSmithKline Vaccines Srl tramitó un H2020: H2020-MSCA-IF-2014 Vaccines are the most effective way to protect humans from infectious disease and may save over 2 million lives per year (Delany, 2013). A k...
2015-05-18 - 2017-06-14 | Financiado

NEWCARBOVAX: New generation of carbohydrate based vaccines via rational understanding of their immunological mech... GlaxoSmithKline Vaccines Srl participó en un H2020: H2020-MSCA-IF-2014 Glycoconjugate vaccines have provided enormous health benefits globally, but they have been less successful in some populations at high risk...
2015-05-18 - 2019-12-31 | Financiado

DiViNe: Sustainable downstream processing of vaccines through incorporation of nanobiotechnologies novel a... GlaxoSmithKline Vaccines Srl participó en un H2020: H2020-BIOTEC-2014-2015 In the vaccine industry, downstream processing is of extreme importance. Prophylactic vaccines aim at protecting healthy people, so any cont...
2015-02-11 - 2020-02-29 | Financiado

IMMUNOSHAPE: Development of Selective Carbohydrate Immunomodulators Targeting C type Lectin Receptors on Antigen... GlaxoSmithKline Vaccines Srl participó en un H2020: H2020-MSCA-ITN-2014 IMMUNOSHAPE aims at training a new generation of scientists that will be capable of combining state of the art synthesis and screening techn...
2014-12-12 - 2018-12-31 | Financiado

FLUCOP: Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protect... GlaxoSmithKline Vaccines Srl participó en un FP6: Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Infl...
2015-03-01 - 2020-02-29 | Financiado

BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety GlaxoSmithKline Vaccines Srl tramitó un FP6: BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado

RAPP-ID: Development of RApid Point-of-Care test Platforms for Infectious Diseases GlaxoSmithKline Vaccines Srl participó en un FP6: RAPP-ID (Development of RApid Point-of-Care test Platforms for Infectious Diseases”) will develop a Point-of-Care Test (POCT) for rapid (hos...
2011-04-01 - 2016-09-30 | Financiado

DISCO: A multidisciplinary Doctoral Industrial School on novel preventive strategies against E. Coli infect... GlaxoSmithKline Vaccines Srl tramitó un FP7: The doctoral school proposed in DISCo originates from the common interest of Novartis Vaccines (NVD) and the French National Institute of Ag...
Financiado

TCDIFLU: Impact of adjuvants on T cell differentiation after Influenza Vaccination analyzed at the Single Cel... GlaxoSmithKline Vaccines Srl tramitó un FP7: "Mutating viruses and resistance to drugs are the major challenges to overcome in influenza (flu) prevention and treatment. Virus-neutralizi...
Financiado

RESTAVAC: Regulation of Expression of Staphylococcus aureus Vaccine Antigen Candidates GlaxoSmithKline Vaccines Srl tramitó un FP7: Staphylococcus aureus is a commensal of the human skin and nares, and a major cause of skin, and soft tissue as well as invasive infections....
Financiado

MEGALOVAX: In search of new cytomegalovirus vaccine antigens GlaxoSmithKline Vaccines Srl tramitó un FP7: Aim of the project is to search for antigens that induce neutralizing antibodies in mice, which prevent entry of Human cytomegalovirus (HCMV...
Financiado

GSK Vaccines Srl